{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:39:05Z","timestamp":1777865945701,"version":"3.51.4"},"reference-count":21,"publisher":"IMR Press","issue":"1-4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japanese Society for Pharmaceutical Palliative Care and Science"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie"],"abstract":"<jats:p>Background: Prophylactic opioid rescue therapy is often used to manage cancer-related pain. However, the effect of prophylactic rescue therapy in suppressing increases in breakthrough pain due to body movements has not yet been investigated. Therefore, this study aimed to compare the efficacy and safety of prophylactic rescue therapy before and after administration. Methods: This multicenter, retrospective survey was conducted in Japan. Participants were patients with cancer who received prophylactic strong opioid rescue therapy for the first time. The primary endpoint was the suppression of an increase in pain, assessed using a Numerical Rating Scale (NRS), before and after administration of prophylactic rescue due to body movement. Results: The overall analysis (193 cases) showed that prophylactic rescue suppressed the increase in the median NRS value by 3.00 (interquartile range: 1.00\u20134.00, p &lt; 0.001). In addition, subgroup analysis by purpose (meals\/bathing\/rehabilitation\/radiation therapy\/others) also showed a significant reduction in the increase in NRS, with all categories exhibiting a decrease of 2.00 or more. Conclusions: Prophylactic opioid rescue with appropriate patient selection can effectively suppress breakthrough pain caused by body movement.<\/jats:p>","DOI":"10.31083\/pharmazie51655","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:43:54Z","timestamp":1777535034000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Prophylactic Opioid Rescue for Breakthrough Pain Due to Body Movement: A Multicenter Retrospective Study"],"prefix":"10.31083","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3722-9771","authenticated-orcid":true,"given":"Ryo","family":"Taguchi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shizuoka Cancer Center, 411-8777 Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-7374","authenticated-orcid":true,"given":"Rei","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, 244-0806 Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5094-2122","authenticated-orcid":true,"given":"Eiji","family":"Kose","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmacy and Pharmaceutical Science, Juntendo University, 279-0013 Chiba, Japan"},{"name":"Faculty of Pharmacy, Laboratory of Clinical Pharmacology, Juntendo University, 279-0013 Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Hirashima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Showa University Hospital, 142-8666 Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0507-7309","authenticated-orcid":true,"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital, 812-8582 Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4232-6803","authenticated-orcid":true,"given":"Hisamitsu","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Juntendo University Urayasu Hospital, 279-0021 Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018; 29: iv166\u2013iv191.","DOI":"10.1093\/annonc\/mdy152"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Randive S, Mehta V. Breakthrough pain-novel analgesics. Current Clinical Pharmacology. 2012; 7: 116\u2013120.","DOI":"10.2174\/157488412800228893"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Mercadante S, Adile C, Masedu F, Valenti M, Aielli F. Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain. Journal of Pain and Symptom Management. 2019; 57: 966\u2013970.","DOI":"10.1016\/j.jpainsymman.2019.02.014"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mercadante S. Once again\u2026 breakthrough cancer pain: an updated overview. Journal of Anesthesia, Analgesia and Critical Care. 2023; 3: 23.","DOI":"10.1186\/s44158-023-00101-x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E. The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Supportive Care in Cancer. 1999; 7: 265\u2013270.","DOI":"10.1007\/s005200050259"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treatment Reviews. 2006; 32: 304\u2013315.","DOI":"10.1016\/j.ctrv.2006.03.001"},{"key":"ref7","unstructured":"Swegle JM, Logemann C. Management of common opioid-induced adverse effects. American Family Physician. 2006; 74: 1347\u20131354."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Ganguly A, Michael M, Goschin S, Harris K, McFarland DC. Cancer Pain and Opioid Use Disorder. Oncology. 2022; 36: 535\u2013541.","DOI":"10.46883\/2022.25920973"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Weiss RD, Potter JS, Griffin ML, McHugh RK, Haller D, Jacobs P, et al. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. Journal of Substance Abuse Treatment. 2014; 47: 140\u2013145.","DOI":"10.1016\/j.jsat.2014.03.004"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dalal S, Bruera E. Pain Management for Patients With Advanced Cancer in the Opioid Epidemic Era. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2019; 39: 24\u201335.","DOI":"10.1200\/EDBK_100020"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Tanaka R, Ishikawa H, Sato T, Shino M, Omae K, Sato T, et al. Safety profile of prophylactic rescue dosing of immediate-release oral opioids in cancer patients. Journal of Pharmaceutical Health Care and Sciences. 2018; 4: 25.","DOI":"10.1186\/s40780-018-0121-3"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Karcioglu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the pain scales in adults: Which to use? The American Journal of Emergency Medicine. 2018; 36: 707\u2013714.","DOI":"10.1016\/j.ajem.2018.01.008"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emergency Medicine Journal. 2001; 18: 205\u2013207.","DOI":"10.1136\/emj.18.3.205"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Leiva-V\u00e1squez O, Letelier LM, Rojas L, Viviani P, Castellano J, Gonz\u00e1lez A, et al. Is Acetaminophen Beneficial in Patients With Cancer Pain Who are on Strong Opioids? A Randomized Controlled Trial. Journal of Pain and Symptom Management. 2023; 66: 183\u2013192.e1.","DOI":"10.1016\/j.jpainsymman.2023.05.002"},{"key":"ref15","unstructured":"World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization: Geneva. 2018."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Nakamura A, Hasegawa M, Ito H, Minami K, Koike K, Habu-Tomita N, et al. Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl. Journal of Pain & Palliative Care Pharmacotherapy. 2011; 25: 318\u2013334.","DOI":"10.3109\/15360288.2011.620689"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Suzuki T, Nurrochmad A, Ozaki M, Khotib J, Nakamura A, Imai S, et al. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. Neuropharmacology. 2005; 49: 1121\u20131131.","DOI":"10.1016\/j.neuropharm.2005.06.009"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Aubrun F, Mazoit JX, Riou B. Postoperative intravenous morphine titration. British Journal of Anaesthesia. 2012; 108: 193\u2013201.","DOI":"10.1093\/bja\/aer458"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Kwon JH, Tanco K, Park JC, Wong A, Seo L, Liu D, et al. Frequency, Predictors, and Medical Record Documentation of Chemical Coping Among Advanced Cancer Patients. The Oncologist. 2015; 20: 692\u2013697.","DOI":"10.1634\/theoncologist.2015-0012"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Azuma K, Abe H, Hozumi J, Inoue R, Konishi M, Tsuchida R, et al. Prefectural Adequacy of Opioid Availability for Cancer Pain and Its Determinants in Japan: A Preliminary Study. JMA Journal. 2020; 3: 340\u2013346.","DOI":"10.31662\/jmaj.2020-0037"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Onishi E, Kobayashi T, Dexter E, Marino M, Maeno T, Deyo RA. Comparison of Opioid Prescribing Patterns in the United States and Japan: Primary Care Physicians\u2019 Attitudes and Perceptions. Journal of the American Board of Family Medicine. 2017; 30: 248\u2013254.","DOI":"10.3122\/jabfm.2017.02.160299"}],"container-title":["Die Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/1-4\/10.31083\/Pharmazie51655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:44:13Z","timestamp":1777535053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/1-4\/10.31083\/Pharmazie51655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":21,"journal-issue":{"issue":"1-4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0031-7144(26)02754-0"],"URL":"https:\/\/doi.org\/10.31083\/pharmazie51655","relation":{},"ISSN":["0031-7144","3053-691X"],"issn-type":[{"value":"0031-7144","type":"print"},{"value":"3053-691X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"51655"}}